Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glaxo Relenza Program Will Address Diskhaler Ease of Use, Drug Efficacy

Executive Summary

Glaxo plans to monitor patient experience with its Relenza Diskhaler through an "active" Phase IV program for the inhaled antiviral influenza treatment. FDA approved Relenza July 27.

You may also be interested in...



WellPoint Hopes To Curb Relenza Costs By Pushing Flu Vaccination

WellPoint Health Networks is encouraging flu vaccinations in 280,000 letters to members, as part of a campaign to limit use of Glaxo Wellcome's influenza treatment Relenza.

WellPoint Hopes To Curb Relenza Costs By Pushing Flu Vaccination

WellPoint Health Networks is encouraging flu vaccinations in 280,000 letters to members, as part of a campaign to limit use of Glaxo Wellcome's influenza treatment Relenza.

Roche Tamiflu Prevents Flu In More Than 99% Of Frail Elderly - ICAAC

Prophylactic use of Roche's Tamiflu (oseltamivir) reduced the incidence of influenza in an elderly nursing home population to less than 1%, according to preliminary results from a once-daily prevention study presented by Frederick Hayden, MD, University of Virginia, Sept. 27 at the Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel